<DOC>
	<DOC>NCT00389415</DOC>
	<brief_summary>This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients who have completed core study CLAF237A1303.</brief_summary>
	<brief_title>Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis as Type 2 Diabetes Patients who have completed study CLAF237A1303 Outpatients Patients who prematurely discontinued Study CLAF237A1303 Other protocoldefined inclusion/exclusioncriterial may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>